Neoleukin Therapeutics, Inc.
NASDAQ:NLTX
3.49 (USD) • At close December 18, 2023
Overzicht | Financiële gegevens
Bedrijfsnaam | Neoleukin Therapeutics, Inc. |
Symbool | NLTX |
Munteenheid | USD |
Prijs | 3.49 |
Beurswaarde | 8,199,685 |
Dividendpercentage | 0% |
52-weken bereik | 3.42 - 18.8 |
Industrie | Drug Manufacturers—Specialty & Generic |
Sector | Healthcare |
CEO | Ms. Donna M. Cochener-Metcalfe J.D. |
Website | https://www.neoleukin.com |
An error occurred while fetching data.
Over Neoleukin Therapeutics, Inc.
Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)